Platelet aggregation and hemostatic plug formation

Platelet aggregation and hemostatic plug formation is the physiological process by which platelets adhere to damaged blood vessel walls and clump together to stop bleeding. This process, known as primary hemostasis, involves several stages: platelet adhesion to subendothelial collagen via von Willebrand factor, platelet activation and secretion of granules, and finally, aggregation mediated by the binding of fibrinogen to activated glycoprotein IIb/IIIa receptors (StatPearls, 2023). While essential for preventing blood loss after injury, pathological activation of this process can lead to arterial thrombosis, causing life-threatening conditions such as myocardial infarction and ischemic stroke (NIH, 2022). Pharmacological intervention typically involves antiplatelet agents that target specific molecular components of this pathway, such as the P2Y12 ADP receptor or cyclooxygenase-1, to reduce the risk of thrombotic events (PubMed, 2021). These drugs are critical in the management of cardiovascular diseases but carry a significant risk of bleeding complications. Monitoring the efficacy of these interventions often requires specialized assays that measure the extent of platelet inhibition. Understanding the balance between hemostasis and thrombosis is fundamental to developing safer and more effective antithrombotic therapies.

Other names

Primary hemostasisPlatelet plug formationThrombus formationPlatelet clumping

Antiplatelet drugs inhibit this process by blocking specific molecular pathways, such as thromboxane A2 synthesis (COX-1 inhibitors), ADP-mediated signaling (P2Y12 antagonists), or fibrinogen binding (GPIIb/IIIa inhibitors).